| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 234 | 2024 | 16221 | 10.370 |
Why?
|
| Genes, BRCA2 | 49 | 2024 | 321 | 8.520 |
Why?
|
| Genes, BRCA1 | 44 | 2024 | 397 | 7.920 |
Why?
|
| BRCA1 Protein | 52 | 2024 | 526 | 7.790 |
Why?
|
| BRCA2 Protein | 42 | 2024 | 379 | 7.180 |
Why?
|
| Genetic Testing | 47 | 2024 | 1699 | 5.040 |
Why?
|
| Germ-Line Mutation | 34 | 2024 | 1099 | 4.120 |
Why?
|
| Genetic Predisposition to Disease | 77 | 2024 | 5771 | 3.230 |
Why?
|
| Ovarian Neoplasms | 40 | 2023 | 4800 | 2.590 |
Why?
|
| Mutation | 73 | 2024 | 15918 | 2.470 |
Why?
|
| Triple Negative Breast Neoplasms | 18 | 2024 | 1380 | 2.330 |
Why?
|
| Genetic Counseling | 18 | 2024 | 417 | 2.140 |
Why?
|
| Unilateral Breast Neoplasms | 4 | 2023 | 16 | 1.870 |
Why?
|
| Female | 269 | 2024 | 149106 | 1.860 |
Why?
|
| Heterozygote | 25 | 2022 | 1055 | 1.610 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 10 | 2024 | 512 | 1.590 |
Why?
|
| Carcinoma, Ductal, Breast | 17 | 2019 | 1237 | 1.470 |
Why?
|
| Humans | 297 | 2024 | 271550 | 1.400 |
Why?
|
| Mastectomy | 19 | 2022 | 1557 | 1.370 |
Why?
|
| Aromatase Inhibitors | 5 | 2022 | 310 | 1.260 |
Why?
|
| Adult | 138 | 2024 | 82003 | 1.250 |
Why?
|
| Middle Aged | 150 | 2024 | 90422 | 1.230 |
Why?
|
| Receptor, ErbB-2 | 19 | 2021 | 2655 | 1.210 |
Why?
|
| Benzimidazoles | 6 | 2024 | 438 | 1.210 |
Why?
|
| Prophylactic Mastectomy | 5 | 2022 | 37 | 1.200 |
Why?
|
| Biomarkers, Tumor | 30 | 2024 | 10736 | 1.190 |
Why?
|
| Phthalazines | 4 | 2022 | 263 | 1.130 |
Why?
|
| Neoadjuvant Therapy | 25 | 2024 | 5224 | 1.100 |
Why?
|
| Inflammatory Breast Neoplasms | 5 | 2018 | 530 | 1.100 |
Why?
|
| Receptors, Estrogen | 22 | 2020 | 2166 | 1.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 34 | 2024 | 16646 | 1.070 |
Why?
|
| Hereditary Breast and Ovarian Cancer Syndrome | 3 | 2021 | 26 | 1.050 |
Why?
|
| Breast | 12 | 2023 | 1378 | 1.030 |
Why?
|
| Neoplastic Syndromes, Hereditary | 7 | 2021 | 232 | 1.020 |
Why?
|
| Risk Reduction Behavior | 8 | 2024 | 216 | 0.930 |
Why?
|
| Genome-Wide Association Study | 15 | 2021 | 2348 | 0.910 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 7 | 2014 | 695 | 0.900 |
Why?
|
| Carboplatin | 8 | 2024 | 880 | 0.880 |
Why?
|
| Receptors, Progesterone | 13 | 2014 | 1609 | 0.870 |
Why?
|
| Paclitaxel | 13 | 2024 | 2104 | 0.850 |
Why?
|
| Aged | 100 | 2024 | 73451 | 0.850 |
Why?
|
| Chemotherapy, Adjuvant | 19 | 2022 | 3988 | 0.810 |
Why?
|
| Early Detection of Cancer | 7 | 2021 | 1341 | 0.810 |
Why?
|
| Mammography | 9 | 2024 | 1054 | 0.800 |
Why?
|
| Neoplasm Recurrence, Local | 18 | 2023 | 10370 | 0.750 |
Why?
|
| Celecoxib | 2 | 2020 | 198 | 0.750 |
Why?
|
| RNA, Small Interfering | 4 | 2019 | 2203 | 0.730 |
Why?
|
| Breast Carcinoma In Situ | 1 | 2020 | 17 | 0.710 |
Why?
|
| Body Mass Index | 6 | 2019 | 2247 | 0.710 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2018 | 153 | 0.680 |
Why?
|
| Mastectomy, Segmental | 3 | 2024 | 1053 | 0.680 |
Why?
|
| RNAi Therapeutics | 1 | 2019 | 44 | 0.660 |
Why?
|
| Elongation Factor 2 Kinase | 1 | 2019 | 44 | 0.660 |
Why?
|
| Polymorphism, Single Nucleotide | 21 | 2022 | 4651 | 0.640 |
Why?
|
| Disease-Free Survival | 17 | 2024 | 10258 | 0.640 |
Why?
|
| Li-Fraumeni Syndrome | 3 | 2024 | 167 | 0.620 |
Why?
|
| Risk Factors | 47 | 2023 | 17982 | 0.620 |
Why?
|
| Weight Gain | 2 | 2020 | 470 | 0.610 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2018 | 488 | 0.610 |
Why?
|
| Retrospective Studies | 43 | 2023 | 39818 | 0.600 |
Why?
|
| Community Health Services | 1 | 2019 | 129 | 0.600 |
Why?
|
| Lymph Nodes | 7 | 2014 | 3079 | 0.600 |
Why?
|
| Neoplasm Metastasis | 12 | 2024 | 5315 | 0.590 |
Why?
|
| Vulnerable Populations | 2 | 2019 | 188 | 0.580 |
Why?
|
| Neoplasms | 16 | 2024 | 15903 | 0.580 |
Why?
|
| Risk Assessment | 24 | 2024 | 6845 | 0.570 |
Why?
|
| Chemoprevention | 4 | 2024 | 251 | 0.570 |
Why?
|
| Genotype | 13 | 2021 | 4266 | 0.560 |
Why?
|
| Quinolones | 1 | 2018 | 163 | 0.560 |
Why?
|
| Germ Cells | 6 | 2024 | 350 | 0.550 |
Why?
|
| Taxoids | 11 | 2021 | 1007 | 0.540 |
Why?
|
| Antineoplastic Agents | 23 | 2024 | 14631 | 0.530 |
Why?
|
| Nitriles | 4 | 2024 | 938 | 0.520 |
Why?
|
| Tamoxifen | 6 | 2022 | 875 | 0.520 |
Why?
|
| Neoplasm Staging | 31 | 2021 | 14015 | 0.510 |
Why?
|
| Risk Management | 4 | 2021 | 117 | 0.510 |
Why?
|
| Prognosis | 33 | 2024 | 22524 | 0.500 |
Why?
|
| Neural Stem Cells | 1 | 2017 | 183 | 0.500 |
Why?
|
| Pilot Projects | 8 | 2022 | 2857 | 0.500 |
Why?
|
| Deoxycytidine | 4 | 2018 | 1390 | 0.490 |
Why?
|
| Hormone Replacement Therapy | 2 | 2016 | 215 | 0.490 |
Why?
|
| Cancer Care Facilities | 2 | 2020 | 908 | 0.490 |
Why?
|
| Carcinoma, Medullary | 2 | 2014 | 248 | 0.490 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 2 | 2017 | 135 | 0.480 |
Why?
|
| Imatinib Mesylate | 2 | 2018 | 1690 | 0.480 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2024 | 3675 | 0.470 |
Why?
|
| Practice Guidelines as Topic | 8 | 2024 | 2422 | 0.460 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 562 | 0.460 |
Why?
|
| Carcinoma in Situ | 4 | 2012 | 495 | 0.440 |
Why?
|
| Yoga | 4 | 2017 | 88 | 0.430 |
Why?
|
| Biopsy, Fine-Needle | 7 | 2020 | 701 | 0.430 |
Why?
|
| Thiolester Hydrolases | 1 | 2013 | 36 | 0.420 |
Why?
|
| Carcinoma, Lobular | 6 | 2019 | 618 | 0.420 |
Why?
|
| Treatment Outcome | 32 | 2024 | 33870 | 0.420 |
Why?
|
| Counselors | 2 | 2023 | 27 | 0.400 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2012 | 769 | 0.390 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2018 | 6264 | 0.390 |
Why?
|
| Genetic Loci | 5 | 2017 | 502 | 0.380 |
Why?
|
| Anticarcinogenic Agents | 4 | 2012 | 368 | 0.380 |
Why?
|
| Pedigree | 9 | 2024 | 2041 | 0.380 |
Why?
|
| Doxorubicin | 11 | 2024 | 3144 | 0.380 |
Why?
|
| Selective Estrogen Receptor Modulators | 4 | 2011 | 129 | 0.380 |
Why?
|
| Triazoles | 3 | 2011 | 629 | 0.370 |
Why?
|
| Carcinoma | 7 | 2014 | 2621 | 0.360 |
Why?
|
| Cyclophosphamide | 11 | 2024 | 3244 | 0.360 |
Why?
|
| Piperazines | 3 | 2015 | 2145 | 0.360 |
Why?
|
| Age of Onset | 2 | 2015 | 857 | 0.350 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2010 | 67 | 0.350 |
Why?
|
| Ovariectomy | 5 | 2016 | 371 | 0.350 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 3 | 2005 | 231 | 0.350 |
Why?
|
| Bone Density | 1 | 2013 | 464 | 0.350 |
Why?
|
| Young Adult | 23 | 2022 | 22190 | 0.350 |
Why?
|
| Neoplasms, Hormone-Dependent | 5 | 2012 | 347 | 0.350 |
Why?
|
| Primary Prevention | 3 | 2010 | 238 | 0.350 |
Why?
|
| Prospective Studies | 15 | 2022 | 13385 | 0.340 |
Why?
|
| Models, Statistical | 4 | 2010 | 1187 | 0.340 |
Why?
|
| Premenopause | 5 | 2024 | 139 | 0.330 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2019 | 9053 | 0.330 |
Why?
|
| Quality of Life | 13 | 2022 | 4764 | 0.330 |
Why?
|
| Quantitative Trait Loci | 6 | 2021 | 384 | 0.320 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2019 | 105 | 0.320 |
Why?
|
| Proportional Hazards Models | 10 | 2019 | 5099 | 0.320 |
Why?
|
| Survivors | 4 | 2018 | 1023 | 0.310 |
Why?
|
| Survival Rate | 14 | 2021 | 12528 | 0.310 |
Why?
|
| Delivery of Health Care | 1 | 2015 | 876 | 0.310 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 3 | 2020 | 156 | 0.310 |
Why?
|
| Computer Simulation | 3 | 2017 | 1574 | 0.300 |
Why?
|
| Body Height | 2 | 2019 | 235 | 0.300 |
Why?
|
| Risk | 11 | 2016 | 1943 | 0.300 |
Why?
|
| Breast Neoplasms, Male | 5 | 2015 | 233 | 0.300 |
Why?
|
| Dietary Supplements | 2 | 2024 | 559 | 0.300 |
Why?
|
| Genetic Carrier Screening | 2 | 2019 | 101 | 0.300 |
Why?
|
| Therapeutic Irrigation | 2 | 2007 | 93 | 0.300 |
Why?
|
| Genital Neoplasms, Female | 1 | 2015 | 790 | 0.300 |
Why?
|
| Ki-67 Antigen | 3 | 2023 | 682 | 0.290 |
Why?
|
| Logistic Models | 6 | 2018 | 3455 | 0.290 |
Why?
|
| Inheritance Patterns | 2 | 2019 | 136 | 0.290 |
Why?
|
| Alleles | 7 | 2021 | 2594 | 0.290 |
Why?
|
| Follow-Up Studies | 15 | 2019 | 15247 | 0.290 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2024 | 1233 | 0.280 |
Why?
|
| Neoplasms, Second Primary | 3 | 2019 | 1387 | 0.280 |
Why?
|
| Fatigue | 9 | 2018 | 1279 | 0.280 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 2 | 2020 | 30 | 0.280 |
Why?
|
| Drug Administration Schedule | 7 | 2020 | 3531 | 0.280 |
Why?
|
| Incidence | 8 | 2018 | 5848 | 0.280 |
Why?
|
| Sleep Wake Disorders | 3 | 2020 | 373 | 0.280 |
Why?
|
| Case-Control Studies | 14 | 2020 | 6234 | 0.270 |
Why?
|
| Body Fluids | 1 | 2007 | 125 | 0.270 |
Why?
|
| Cytodiagnosis | 2 | 2006 | 226 | 0.270 |
Why?
|
| Clinical Trials as Topic | 5 | 2010 | 3850 | 0.270 |
Why?
|
| Postmenopause | 3 | 2017 | 378 | 0.270 |
Why?
|
| Predictive Value of Tests | 9 | 2021 | 4976 | 0.270 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2004 | 177 | 0.270 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2024 | 564 | 0.270 |
Why?
|
| Glioblastoma | 1 | 2017 | 1774 | 0.270 |
Why?
|
| Genetic Variation | 4 | 2019 | 2166 | 0.260 |
Why?
|
| Attitude to Health | 1 | 2009 | 439 | 0.260 |
Why?
|
| Chromosome Mapping | 3 | 2020 | 1655 | 0.260 |
Why?
|
| B7-H1 Antigen | 3 | 2024 | 1071 | 0.260 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2020 | 631 | 0.260 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2005 | 84 | 0.250 |
Why?
|
| Prostatic Neoplasms | 5 | 2021 | 5870 | 0.250 |
Why?
|
| Chromosomal Instability | 1 | 2006 | 229 | 0.250 |
Why?
|
| Genes, bcl-2 | 1 | 2005 | 173 | 0.240 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2017 | 520 | 0.240 |
Why?
|
| Weight Loss | 2 | 2020 | 634 | 0.240 |
Why?
|
| Oncologists | 2 | 2024 | 136 | 0.240 |
Why?
|
| Mammary Glands, Human | 2 | 2015 | 184 | 0.240 |
Why?
|
| Preimplantation Diagnosis | 3 | 2014 | 37 | 0.240 |
Why?
|
| Breast Density | 1 | 2024 | 20 | 0.240 |
Why?
|
| Radiotherapy, Intensity-Modulated | 3 | 2021 | 2164 | 0.240 |
Why?
|
| Cholecalciferol | 1 | 2024 | 49 | 0.230 |
Why?
|
| Patient Selection | 3 | 2012 | 2033 | 0.230 |
Why?
|
| Genetic Association Studies | 3 | 2019 | 1095 | 0.230 |
Why?
|
| Aged, 80 and over | 24 | 2018 | 31066 | 0.230 |
Why?
|
| Cohort Studies | 9 | 2024 | 9477 | 0.230 |
Why?
|
| Ataxia Telangiectasia | 2 | 2021 | 62 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2020 | 7916 | 0.230 |
Why?
|
| Telemedicine | 2 | 2021 | 554 | 0.220 |
Why?
|
| Genes, p53 | 4 | 2024 | 1145 | 0.220 |
Why?
|
| Meditation | 2 | 2016 | 78 | 0.220 |
Why?
|
| Phenylthiohydantoin | 1 | 2024 | 103 | 0.220 |
Why?
|
| DNA Repair | 4 | 2021 | 1911 | 0.220 |
Why?
|
| Lung Neoplasms | 6 | 2019 | 12032 | 0.220 |
Why?
|
| Exons | 4 | 2016 | 1384 | 0.220 |
Why?
|
| Catechin | 2 | 2014 | 34 | 0.220 |
Why?
|
| Medication Adherence | 2 | 2019 | 519 | 0.220 |
Why?
|
| Fluorouracil | 9 | 2017 | 1989 | 0.220 |
Why?
|
| Actigraphy | 2 | 2020 | 55 | 0.220 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 250 | 0.210 |
Why?
|
| Age Factors | 9 | 2018 | 5502 | 0.210 |
Why?
|
| Protein Folding | 1 | 2024 | 298 | 0.210 |
Why?
|
| Mobile Applications | 1 | 2024 | 109 | 0.210 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2012 | 837 | 0.210 |
Why?
|
| Time Factors | 13 | 2019 | 13077 | 0.210 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2024 | 5407 | 0.210 |
Why?
|
| Estrogens | 5 | 2023 | 816 | 0.200 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2006 | 2314 | 0.200 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2021 | 10 | 0.200 |
Why?
|
| DNA-Binding Proteins | 3 | 2011 | 5030 | 0.190 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 4955 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 1545 | 0.190 |
Why?
|
| Vitamin D | 2 | 2024 | 262 | 0.190 |
Why?
|
| Extracellular Vesicles | 1 | 2023 | 135 | 0.190 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 274 | 0.190 |
Why?
|
| ErbB Receptors | 4 | 2024 | 2380 | 0.190 |
Why?
|
| Direct-To-Consumer Screening and Testing | 1 | 2021 | 14 | 0.190 |
Why?
|
| Chemoradiotherapy | 3 | 2018 | 2028 | 0.190 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2001 | 47 | 0.190 |
Why?
|
| Neoplasm Proteins | 3 | 2019 | 3351 | 0.190 |
Why?
|
| Qualitative Research | 1 | 2024 | 645 | 0.190 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 5185 | 0.180 |
Why?
|
| Cyclooxygenase 2 | 4 | 2009 | 496 | 0.180 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 73 | 0.180 |
Why?
|
| Anthracyclines | 3 | 2021 | 339 | 0.180 |
Why?
|
| Spermine Synthase | 1 | 2020 | 6 | 0.180 |
Why?
|
| Depression | 6 | 2017 | 1730 | 0.180 |
Why?
|
| Patients | 1 | 2023 | 248 | 0.180 |
Why?
|
| Spermine | 1 | 2020 | 25 | 0.180 |
Why?
|
| Formaldehyde | 1 | 2020 | 117 | 0.180 |
Why?
|
| ROC Curve | 4 | 2018 | 1250 | 0.180 |
Why?
|
| Topotecan | 1 | 2001 | 248 | 0.180 |
Why?
|
| Fanconi Anemia | 1 | 2020 | 91 | 0.180 |
Why?
|
| Administration, Oral | 2 | 2019 | 1620 | 0.180 |
Why?
|
| Apoptosis | 5 | 2011 | 7783 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2018 | 5082 | 0.180 |
Why?
|
| Plant Extracts | 2 | 2014 | 224 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 4961 | 0.170 |
Why?
|
| United States | 13 | 2021 | 16006 | 0.170 |
Why?
|
| Benzamides | 2 | 2024 | 1879 | 0.170 |
Why?
|
| Jews | 3 | 2015 | 57 | 0.170 |
Why?
|
| Cobalt | 1 | 2019 | 57 | 0.170 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2000 | 195 | 0.170 |
Why?
|
| Clone Cells | 1 | 2021 | 588 | 0.170 |
Why?
|
| Accreditation | 1 | 2020 | 137 | 0.170 |
Why?
|
| Adolescent | 13 | 2022 | 32726 | 0.170 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2024 | 638 | 0.170 |
Why?
|
| Radiation Oncologists | 1 | 2019 | 31 | 0.170 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 2 | 2017 | 162 | 0.170 |
Why?
|
| Intersectoral Collaboration | 1 | 2019 | 42 | 0.170 |
Why?
|
| Nanomedicine | 1 | 2019 | 53 | 0.170 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 64 | 0.170 |
Why?
|
| Mice, Nude | 3 | 2019 | 4348 | 0.160 |
Why?
|
| Weight Reduction Programs | 1 | 2020 | 74 | 0.160 |
Why?
|
| Cyclin E | 1 | 2021 | 283 | 0.160 |
Why?
|
| Ferric Compounds | 1 | 2019 | 77 | 0.160 |
Why?
|
| Decision Making | 5 | 2024 | 1250 | 0.160 |
Why?
|
| Survival Analysis | 5 | 2023 | 9307 | 0.160 |
Why?
|
| Genes, Retinoblastoma | 1 | 1999 | 92 | 0.160 |
Why?
|
| Evolution, Molecular | 2 | 2021 | 868 | 0.160 |
Why?
|
| Cell Line, Tumor | 8 | 2021 | 14818 | 0.160 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2000 | 129 | 0.160 |
Why?
|
| Hyperplasia | 4 | 2019 | 580 | 0.160 |
Why?
|
| Male | 31 | 2024 | 128724 | 0.160 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 858 | 0.160 |
Why?
|
| Health Personnel | 3 | 2021 | 657 | 0.160 |
Why?
|
| Medical Oncology | 2 | 2019 | 1462 | 0.160 |
Why?
|
| Referral and Consultation | 2 | 2021 | 939 | 0.160 |
Why?
|
| Estrogen Receptor alpha | 3 | 2023 | 693 | 0.160 |
Why?
|
| Cellular Reprogramming | 1 | 2020 | 202 | 0.160 |
Why?
|
| Developing Countries | 1 | 2021 | 340 | 0.160 |
Why?
|
| Carbolines | 1 | 2018 | 30 | 0.160 |
Why?
|
| Raloxifene Hydrochloride | 3 | 2011 | 47 | 0.160 |
Why?
|
| Jordan | 1 | 2018 | 25 | 0.150 |
Why?
|
| Cell Proliferation | 4 | 2021 | 7259 | 0.150 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1999 | 149 | 0.150 |
Why?
|
| Precancerous Conditions | 3 | 2011 | 1065 | 0.150 |
Why?
|
| Biomarkers | 4 | 2019 | 5086 | 0.150 |
Why?
|
| Cancer Survivors | 2 | 2022 | 744 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 4337 | 0.150 |
Why?
|
| Linkage Disequilibrium | 4 | 2021 | 495 | 0.150 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2018 | 126 | 0.150 |
Why?
|
| Gene Transfer Techniques | 2 | 2019 | 804 | 0.150 |
Why?
|
| Life Style | 2 | 2021 | 621 | 0.150 |
Why?
|
| Health Services Accessibility | 3 | 2019 | 817 | 0.140 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 787 | 0.140 |
Why?
|
| Reproductive Behavior | 1 | 2016 | 10 | 0.140 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2017 | 607 | 0.140 |
Why?
|
| Lymphatic Metastasis | 7 | 2011 | 4965 | 0.140 |
Why?
|
| Surveys and Questionnaires | 8 | 2024 | 5936 | 0.140 |
Why?
|
| Internationality | 1 | 2018 | 206 | 0.140 |
Why?
|
| Cross-Cultural Comparison | 1 | 2017 | 92 | 0.140 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 405 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2004 | 1265 | 0.140 |
Why?
|
| Gene Expression Profiling | 9 | 2023 | 5163 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2018 | 5566 | 0.140 |
Why?
|
| Carrier Proteins | 2 | 2016 | 2120 | 0.140 |
Why?
|
| Bayes Theorem | 3 | 2022 | 1056 | 0.140 |
Why?
|
| DNA Modification Methylases | 1 | 2017 | 175 | 0.130 |
Why?
|
| Societies, Medical | 2 | 2020 | 1347 | 0.130 |
Why?
|
| Dacarbazine | 2 | 2017 | 503 | 0.130 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2016 | 24 | 0.130 |
Why?
|
| Population Surveillance | 2 | 2016 | 649 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2016 | 157 | 0.130 |
Why?
|
| Morpholines | 2 | 2009 | 296 | 0.130 |
Why?
|
| Radiation Tolerance | 1 | 2019 | 636 | 0.130 |
Why?
|
| Colorectal Neoplasms | 3 | 2022 | 3708 | 0.130 |
Why?
|
| MicroRNAs | 2 | 2023 | 2902 | 0.130 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 146 | 0.130 |
Why?
|
| Quality Improvement | 2 | 2023 | 919 | 0.130 |
Why?
|
| Autophagy | 2 | 2015 | 912 | 0.130 |
Why?
|
| Cholesterol | 2 | 2016 | 659 | 0.130 |
Why?
|
| Guideline Adherence | 1 | 2020 | 643 | 0.130 |
Why?
|
| Feasibility Studies | 6 | 2021 | 2364 | 0.130 |
Why?
|
| Laryngeal Neoplasms | 1 | 2019 | 533 | 0.130 |
Why?
|
| DNA Repair Enzymes | 1 | 2017 | 235 | 0.130 |
Why?
|
| Adenocarcinoma | 4 | 2005 | 7937 | 0.130 |
Why?
|
| Gene Frequency | 2 | 2016 | 1248 | 0.130 |
Why?
|
| Endometrial Neoplasms | 2 | 2005 | 1389 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2016 | 198 | 0.130 |
Why?
|
| Signal Transduction | 7 | 2024 | 12134 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2016 | 299 | 0.120 |
Why?
|
| Genes, Mitochondrial | 1 | 2015 | 26 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2017 | 2324 | 0.120 |
Why?
|
| Hospitals, Community | 1 | 2015 | 81 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 8 | 2012 | 4061 | 0.120 |
Why?
|
| Models, Organizational | 1 | 2015 | 75 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 204 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2019 | 402 | 0.120 |
Why?
|
| Reproductive History | 1 | 2014 | 23 | 0.120 |
Why?
|
| Radiology | 1 | 2020 | 428 | 0.120 |
Why?
|
| Phenotype | 6 | 2019 | 6493 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2022 | 1092 | 0.120 |
Why?
|
| Cadherins | 2 | 2010 | 671 | 0.120 |
Why?
|
| Sleep | 2 | 2017 | 443 | 0.120 |
Why?
|
| Trastuzumab | 4 | 2024 | 742 | 0.120 |
Why?
|
| Nanoparticles | 1 | 2019 | 585 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2016 | 293 | 0.120 |
Why?
|
| Quality of Health Care | 1 | 2019 | 629 | 0.120 |
Why?
|
| Animals | 14 | 2020 | 62359 | 0.120 |
Why?
|
| Duty to Recontact | 2 | 2024 | 8 | 0.120 |
Why?
|
| Tea | 1 | 2014 | 44 | 0.120 |
Why?
|
| Propensity Score | 1 | 2017 | 773 | 0.120 |
Why?
|
| Proteomics | 2 | 2020 | 1431 | 0.110 |
Why?
|
| Counseling | 1 | 2016 | 382 | 0.110 |
Why?
|
| Genes, myc | 1 | 2015 | 374 | 0.110 |
Why?
|
| DNA Glycosylases | 1 | 2014 | 88 | 0.110 |
Why?
|
| Thymidylate Synthase | 1 | 2013 | 57 | 0.110 |
Why?
|
| Area Under Curve | 2 | 2014 | 729 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2018 | 807 | 0.110 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 549 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 3 | 2005 | 4493 | 0.110 |
Why?
|
| Hip | 1 | 2013 | 26 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 1950 | 0.110 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2014 | 126 | 0.110 |
Why?
|
| Radiotherapy, Conformal | 1 | 2018 | 898 | 0.110 |
Why?
|
| 3' Flanking Region | 1 | 2012 | 8 | 0.110 |
Why?
|
| 5' Flanking Region | 1 | 2012 | 21 | 0.110 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 6205 | 0.110 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 1051 | 0.110 |
Why?
|
| Models, Genetic | 2 | 2021 | 1166 | 0.110 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2014 | 143 | 0.110 |
Why?
|
| Transcriptome | 2 | 2020 | 1953 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 549 | 0.110 |
Why?
|
| Exercise | 2 | 2020 | 1209 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 560 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2015 | 488 | 0.100 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2014 | 227 | 0.100 |
Why?
|
| Neoplasm Grading | 2 | 2014 | 1823 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2016 | 2325 | 0.100 |
Why?
|
| Infertility, Female | 1 | 2014 | 212 | 0.100 |
Why?
|
| Cisplatin | 1 | 2020 | 2501 | 0.100 |
Why?
|
| Paget's Disease, Mammary | 1 | 2012 | 40 | 0.100 |
Why?
|
| Radiotherapy Dosage | 2 | 2019 | 3999 | 0.100 |
Why?
|
| Structure-Activity Relationship | 2 | 2024 | 982 | 0.100 |
Why?
|
| Affect | 1 | 2014 | 306 | 0.100 |
Why?
|
| Estrogen Antagonists | 2 | 2024 | 188 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2016 | 678 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2018 | 3908 | 0.100 |
Why?
|
| Lumbar Vertebrae | 1 | 2013 | 249 | 0.100 |
Why?
|
| Aromatase | 1 | 2011 | 57 | 0.100 |
Why?
|
| Cell Survival | 3 | 2015 | 3068 | 0.100 |
Why?
|
| Immunohistochemistry | 8 | 2009 | 7790 | 0.100 |
Why?
|
| Gene Duplication | 1 | 2014 | 433 | 0.100 |
Why?
|
| DNA Mutational Analysis | 5 | 2021 | 2357 | 0.090 |
Why?
|
| Texas | 3 | 2015 | 6444 | 0.090 |
Why?
|
| Stathmin | 1 | 2010 | 31 | 0.090 |
Why?
|
| Professional-Patient Relations | 1 | 2011 | 114 | 0.090 |
Why?
|
| Gamma Rays | 1 | 2012 | 239 | 0.090 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2011 | 110 | 0.090 |
Why?
|
| Breathing Exercises | 1 | 2010 | 23 | 0.090 |
Why?
|
| Goserelin | 1 | 2010 | 18 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 663 | 0.090 |
Why?
|
| Adenovirus E1A Proteins | 1 | 2011 | 165 | 0.090 |
Why?
|
| Double-Blind Method | 4 | 2020 | 2588 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 4807 | 0.090 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2010 | 20 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 618 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2016 | 413 | 0.090 |
Why?
|
| Models, Economic | 1 | 2010 | 102 | 0.090 |
Why?
|
| Triage | 1 | 2012 | 258 | 0.090 |
Why?
|
| Cell Cycle Proteins | 2 | 2016 | 2122 | 0.090 |
Why?
|
| Contrast Media | 1 | 2017 | 1504 | 0.090 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2014 | 481 | 0.090 |
Why?
|
| Life Expectancy | 1 | 2010 | 129 | 0.090 |
Why?
|
| Hemangiosarcoma | 1 | 2012 | 238 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 2078 | 0.090 |
Why?
|
| Radiosurgery | 1 | 2019 | 1378 | 0.090 |
Why?
|
| Quinazolines | 2 | 2015 | 956 | 0.090 |
Why?
|
| Fallopian Tubes | 1 | 2010 | 131 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2390 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 1320 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2013 | 1578 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2020 | 4157 | 0.090 |
Why?
|
| Preoperative Period | 1 | 2010 | 348 | 0.090 |
Why?
|
| Telomerase | 1 | 2013 | 547 | 0.080 |
Why?
|
| Bridged-Ring Compounds | 1 | 2010 | 180 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2010 | 299 | 0.080 |
Why?
|
| Telomere | 1 | 2013 | 550 | 0.080 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2009 | 72 | 0.080 |
Why?
|
| Haplotypes | 4 | 2016 | 912 | 0.080 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2017 | 554 | 0.080 |
Why?
|
| Phytotherapy | 1 | 2010 | 103 | 0.080 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2010 | 163 | 0.080 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2010 | 236 | 0.080 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 543 | 0.080 |
Why?
|
| Decision Support Techniques | 2 | 2024 | 604 | 0.080 |
Why?
|
| Gene Silencing | 2 | 2010 | 827 | 0.080 |
Why?
|
| Information Dissemination | 1 | 2011 | 271 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 1899 | 0.080 |
Why?
|
| Gene Deletion | 1 | 2014 | 1475 | 0.080 |
Why?
|
| Annexin A1 | 1 | 2008 | 41 | 0.080 |
Why?
|
| Diet | 1 | 2016 | 1483 | 0.080 |
Why?
|
| Patient Satisfaction | 2 | 2010 | 915 | 0.080 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 9049 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2008 | 27 | 0.080 |
Why?
|
| Anxiety | 2 | 2014 | 1234 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1403 | 0.080 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2021 | 437 | 0.080 |
Why?
|
| Polysaccharides | 1 | 2009 | 195 | 0.080 |
Why?
|
| Internet | 3 | 2024 | 704 | 0.080 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2020 | 257 | 0.080 |
Why?
|
| Functional Laterality | 1 | 2009 | 284 | 0.070 |
Why?
|
| Genomic Instability | 2 | 2021 | 522 | 0.070 |
Why?
|
| Collagen Type IV | 1 | 2008 | 107 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2008 | 86 | 0.070 |
Why?
|
| Cyclin D1 | 1 | 2010 | 592 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1999 | 1916 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2009 | 198 | 0.070 |
Why?
|
| Cognition Disorders | 1 | 2013 | 764 | 0.070 |
Why?
|
| Health Surveys | 1 | 2009 | 401 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2011 | 3496 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2022 | 1012 | 0.070 |
Why?
|
| Research Design | 3 | 2024 | 1574 | 0.070 |
Why?
|
| Gene Expression | 4 | 2020 | 3658 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 2 | 2015 | 5252 | 0.070 |
Why?
|
| Consensus | 2 | 2024 | 1115 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2014 | 2282 | 0.070 |
Why?
|
| Loss of Heterozygosity | 2 | 2021 | 624 | 0.070 |
Why?
|
| Probability | 1 | 2009 | 885 | 0.070 |
Why?
|
| Monte Carlo Method | 1 | 2010 | 704 | 0.070 |
Why?
|
| RNA, Messenger | 5 | 2022 | 6436 | 0.070 |
Why?
|
| Tertiary Care Centers | 2 | 2020 | 420 | 0.070 |
Why?
|
| Salpingostomy | 1 | 2006 | 8 | 0.070 |
Why?
|
| Perception | 1 | 2009 | 350 | 0.070 |
Why?
|
| Medical Records | 1 | 2008 | 446 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2020 | 7011 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2013 | 2482 | 0.070 |
Why?
|
| Mice | 7 | 2020 | 35697 | 0.070 |
Why?
|
| Muscle Stretching Exercises | 2 | 2017 | 14 | 0.070 |
Why?
|
| Base Sequence | 3 | 2021 | 5453 | 0.070 |
Why?
|
| Epirubicin | 3 | 2017 | 159 | 0.070 |
Why?
|
| beta Catenin | 1 | 2010 | 691 | 0.070 |
Why?
|
| Antibodies | 1 | 2009 | 816 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 968 | 0.070 |
Why?
|
| Brachytherapy | 1 | 2012 | 1005 | 0.070 |
Why?
|
| Biopsy, Needle | 2 | 2007 | 1401 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 663 | 0.070 |
Why?
|
| Software | 1 | 2013 | 1392 | 0.060 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 3022 | 0.060 |
Why?
|
| Prevalence | 2 | 2008 | 3413 | 0.060 |
Why?
|
| Models, Biological | 2 | 2005 | 3207 | 0.060 |
Why?
|
| Receptors, GABA-A | 1 | 2005 | 83 | 0.060 |
Why?
|
| Membrane Proteins | 3 | 2005 | 2949 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 4505 | 0.060 |
Why?
|
| Transglutaminases | 1 | 2005 | 99 | 0.060 |
Why?
|
| Interleukin-2 | 2 | 1999 | 889 | 0.060 |
Why?
|
| Receptors, Chemokine | 1 | 2005 | 114 | 0.060 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2006 | 155 | 0.060 |
Why?
|
| Health Care Costs | 1 | 2010 | 699 | 0.060 |
Why?
|
| DNA Copy Number Variations | 2 | 2022 | 1554 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2006 | 329 | 0.060 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 1984 | 128 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2006 | 355 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2005 | 247 | 0.060 |
Why?
|
| Disease Progression | 5 | 2011 | 6857 | 0.060 |
Why?
|
| Transcription Factors | 3 | 2017 | 5451 | 0.060 |
Why?
|
| Estradiol | 2 | 2023 | 835 | 0.060 |
Why?
|
| Interferon-alpha | 2 | 1999 | 962 | 0.060 |
Why?
|
| Mass Screening | 2 | 2021 | 1550 | 0.060 |
Why?
|
| Methotrexate | 1 | 2008 | 1030 | 0.060 |
Why?
|
| Europe | 2 | 2017 | 661 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 1559 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2011 | 1935 | 0.060 |
Why?
|
| Breast Feeding | 1 | 2005 | 244 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2004 | 126 | 0.060 |
Why?
|
| Databases, Genetic | 2 | 2018 | 757 | 0.060 |
Why?
|
| RNA Interference | 1 | 2008 | 1389 | 0.060 |
Why?
|
| Hydrocortisone | 2 | 2016 | 403 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 1121 | 0.060 |
Why?
|
| Receptors, CXCR4 | 1 | 2005 | 279 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 4139 | 0.050 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2024 | 163 | 0.050 |
Why?
|
| Health Promotion | 1 | 2007 | 510 | 0.050 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2023 | 131 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 3 | 2012 | 1322 | 0.050 |
Why?
|
| Aging | 1 | 2011 | 1555 | 0.050 |
Why?
|
| tau Proteins | 1 | 2005 | 217 | 0.050 |
Why?
|
| DNA | 1 | 2011 | 3055 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2006 | 668 | 0.050 |
Why?
|
| Adult Children | 1 | 2022 | 11 | 0.050 |
Why?
|
| Florida | 1 | 2022 | 115 | 0.050 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2024 | 189 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2005 | 530 | 0.050 |
Why?
|
| Cytokines | 2 | 2019 | 2825 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 527 | 0.050 |
Why?
|
| Hormones | 1 | 2024 | 292 | 0.050 |
Why?
|
| Physicians | 1 | 2010 | 871 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 2616 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2024 | 530 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 4380 | 0.050 |
Why?
|
| Arabs | 1 | 2021 | 33 | 0.050 |
Why?
|
| Sulfonamides | 2 | 2017 | 1932 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 655 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2003 | 1204 | 0.050 |
Why?
|
| Mutation, Missense | 2 | 2023 | 1193 | 0.050 |
Why?
|
| Africa, Northern | 1 | 2021 | 12 | 0.050 |
Why?
|
| Single Molecule Imaging | 1 | 2021 | 9 | 0.050 |
Why?
|
| Salpingo-oophorectomy | 1 | 2021 | 50 | 0.050 |
Why?
|
| Breast Self-Examination | 1 | 2021 | 17 | 0.050 |
Why?
|
| Binding Sites | 2 | 2017 | 2260 | 0.050 |
Why?
|
| France | 1 | 2021 | 122 | 0.050 |
Why?
|
| Endothelin-Converting Enzymes | 1 | 2001 | 2 | 0.050 |
Why?
|
| Middle East | 1 | 2021 | 44 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 2359 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2022 | 463 | 0.050 |
Why?
|
| Endothelin-1 | 1 | 2001 | 62 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 4249 | 0.050 |
Why?
|
| Platinum | 1 | 2021 | 143 | 0.050 |
Why?
|
| Metaplasia | 1 | 2022 | 387 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 7792 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2019 | 1071 | 0.050 |
Why?
|
| Carcinogenesis | 2 | 2018 | 1035 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 2001 | 176 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2021 | 220 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 2001 | 221 | 0.040 |
Why?
|
| K562 Cells | 1 | 2020 | 345 | 0.040 |
Why?
|
| Nutrition Therapy | 1 | 2020 | 23 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2022 | 1138 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2002 | 233 | 0.040 |
Why?
|
| Income | 1 | 2021 | 230 | 0.040 |
Why?
|
| Oncogenes | 1 | 2023 | 700 | 0.040 |
Why?
|
| Data Collection | 2 | 2014 | 625 | 0.040 |
Why?
|
| Pentostatin | 1 | 2000 | 121 | 0.040 |
Why?
|
| Genes, Neoplasm | 1 | 2021 | 315 | 0.040 |
Why?
|
| Telephone | 1 | 2020 | 160 | 0.040 |
Why?
|
| Obesity | 1 | 2012 | 2915 | 0.040 |
Why?
|
| Kallikreins | 1 | 2019 | 86 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2006 | 1453 | 0.040 |
Why?
|
| Granulocytes | 1 | 2000 | 243 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 745 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 3220 | 0.040 |
Why?
|
| Splenectomy | 1 | 2000 | 168 | 0.040 |
Why?
|
| Down-Regulation | 3 | 2011 | 2096 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2002 | 1076 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2021 | 299 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 357 | 0.040 |
Why?
|
| Menopause | 1 | 2019 | 161 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2019 | 71 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 149 | 0.040 |
Why?
|
| Saudi Arabia | 1 | 2018 | 48 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2005 | 3396 | 0.040 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1999 | 39 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2019 | 176 | 0.040 |
Why?
|
| Staurosporine | 1 | 1999 | 147 | 0.040 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 421 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2006 | 1713 | 0.040 |
Why?
|
| Erythropoietin | 1 | 2000 | 215 | 0.040 |
Why?
|
| Cladribine | 1 | 2000 | 253 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 2659 | 0.040 |
Why?
|
| Mannosephosphates | 1 | 1998 | 5 | 0.040 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1999 | 101 | 0.040 |
Why?
|
| Interferons | 1 | 2000 | 299 | 0.040 |
Why?
|
| Androgens | 1 | 2021 | 513 | 0.040 |
Why?
|
| Receptor, IGF Type 2 | 1 | 1998 | 14 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2000 | 737 | 0.040 |
Why?
|
| Parity | 2 | 2010 | 136 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 2670 | 0.040 |
Why?
|
| United Kingdom | 1 | 2018 | 288 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2019 | 208 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 864 | 0.040 |
Why?
|
| Leukopenia | 1 | 2018 | 153 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2002 | 1128 | 0.040 |
Why?
|
| Alopecia | 1 | 2018 | 124 | 0.040 |
Why?
|
| Geography | 1 | 2018 | 140 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2021 | 703 | 0.040 |
Why?
|
| Health Care Surveys | 1 | 2019 | 424 | 0.040 |
Why?
|
| Recurrence | 2 | 2012 | 4882 | 0.040 |
Why?
|
| Mitomycin | 1 | 1999 | 213 | 0.040 |
Why?
|
| Cyclin B1 | 1 | 2017 | 60 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2020 | 704 | 0.040 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2017 | 46 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 390 | 0.040 |
Why?
|
| Asia | 1 | 2017 | 155 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2024 | 1713 | 0.040 |
Why?
|
| Pregnancy | 4 | 2014 | 8110 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2012 | 5697 | 0.040 |
Why?
|
| Ultrasonography, Mammary | 1 | 2020 | 387 | 0.040 |
Why?
|
| Heredity | 1 | 2016 | 26 | 0.040 |
Why?
|
| Genomics | 2 | 2020 | 2825 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2019 | 425 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2017 | 163 | 0.030 |
Why?
|
| Protein Binding | 2 | 2016 | 3497 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 552 | 0.030 |
Why?
|
| California | 1 | 2017 | 211 | 0.030 |
Why?
|
| Telomere-Binding Proteins | 1 | 2017 | 92 | 0.030 |
Why?
|
| tRNA Methyltransferases | 1 | 2016 | 15 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 172 | 0.030 |
Why?
|
| Cyclophilins | 1 | 2016 | 29 | 0.030 |
Why?
|
| Proteins | 1 | 2005 | 2050 | 0.030 |
Why?
|
| Alcohol Drinking | 2 | 2010 | 601 | 0.030 |
Why?
|
| Biopsy | 2 | 2021 | 3537 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2024 | 1206 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2017 | 4976 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2023 | 1568 | 0.030 |
Why?
|
| Cognition | 1 | 2002 | 970 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2017 | 280 | 0.030 |
Why?
|
| Syndrome | 1 | 2019 | 1401 | 0.030 |
Why?
|
| Benzodioxoles | 1 | 2015 | 29 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 534 | 0.030 |
Why?
|
| Smoking | 2 | 2019 | 2549 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 759 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2016 | 188 | 0.030 |
Why?
|
| Indazoles | 1 | 2017 | 310 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2008 | 3662 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 629 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2019 | 1029 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2004 | 1540 | 0.030 |
Why?
|
| Tubulin | 1 | 2015 | 202 | 0.030 |
Why?
|
| Nucleotides | 1 | 2015 | 175 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2020 | 1511 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2015 | 241 | 0.030 |
Why?
|
| Dyssomnias | 1 | 2014 | 7 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 920 | 0.030 |
Why?
|
| China | 1 | 2016 | 644 | 0.030 |
Why?
|
| Caribbean Region | 1 | 2014 | 23 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 4894 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2015 | 249 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2020 | 1372 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 107 | 0.030 |
Why?
|
| Capecitabine | 2 | 2006 | 390 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 493 | 0.030 |
Why?
|
| Anemia | 1 | 2000 | 728 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 2033 | 0.030 |
Why?
|
| Family | 1 | 2018 | 777 | 0.030 |
Why?
|
| Aurora Kinase A | 1 | 2015 | 210 | 0.030 |
Why?
|
| Religion | 1 | 2014 | 95 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 1999 | 2048 | 0.030 |
Why?
|
| Computers, Handheld | 1 | 2014 | 61 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 302 | 0.030 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2014 | 155 | 0.030 |
Why?
|
| Nausea | 2 | 2006 | 540 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 443 | 0.030 |
Why?
|
| Saliva | 1 | 2014 | 238 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 2005 | 2323 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 2357 | 0.030 |
Why?
|
| DNA Damage | 1 | 2020 | 1987 | 0.030 |
Why?
|
| Dermis | 1 | 2012 | 63 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 3347 | 0.030 |
Why?
|
| Thrombosis | 1 | 1999 | 753 | 0.030 |
Why?
|
| Phylogeny | 1 | 2015 | 868 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 339 | 0.030 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 1951 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 530 | 0.030 |
Why?
|
| Spirituality | 1 | 2013 | 129 | 0.020 |
Why?
|
| DNA Breaks | 1 | 2012 | 39 | 0.020 |
Why?
|
| Luciferases | 1 | 2013 | 460 | 0.020 |
Why?
|
| DNA Methylation | 2 | 2013 | 2761 | 0.020 |
Why?
|
| Chromatids | 1 | 2012 | 84 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2008 | 2274 | 0.020 |
Why?
|
| Norpregnenes | 1 | 2011 | 5 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2013 | 878 | 0.020 |
Why?
|
| Triglycerides | 1 | 2014 | 609 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 5762 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 1032 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2019 | 885 | 0.020 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2011 | 78 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2013 | 266 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2011 | 91 | 0.020 |
Why?
|
| Fenretinide | 1 | 2011 | 100 | 0.020 |
Why?
|
| Evidence-Based Practice | 1 | 2012 | 130 | 0.020 |
Why?
|
| Pyrrolidines | 1 | 2011 | 114 | 0.020 |
Why?
|
| Medical Informatics | 1 | 2013 | 195 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2011 | 84 | 0.020 |
Why?
|
| Retinoids | 1 | 2011 | 149 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 613 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2010 | 104 | 0.020 |
Why?
|
| Tetrahydronaphthalenes | 1 | 2011 | 114 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 602 | 0.020 |
Why?
|
| Scutellaria | 1 | 2010 | 5 | 0.020 |
Why?
|
| Exome | 1 | 2016 | 1249 | 0.020 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2014 | 443 | 0.020 |
Why?
|
| Thiophenes | 1 | 2011 | 148 | 0.020 |
Why?
|
| Androstadienes | 1 | 2011 | 172 | 0.020 |
Why?
|
| Menarche | 1 | 2010 | 50 | 0.020 |
Why?
|
| Causality | 1 | 2010 | 177 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2009 | 63 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 1999 | 2367 | 0.020 |
Why?
|
| Computational Biology | 1 | 2016 | 1280 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2013 | 612 | 0.020 |
Why?
|
| Mental Health | 1 | 2013 | 412 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2009 | 2438 | 0.020 |
Why?
|
| Mitosis | 1 | 2012 | 691 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2012 | 334 | 0.020 |
Why?
|
| Glucose | 1 | 2015 | 1225 | 0.020 |
Why?
|
| Receptor, ErbB-4 | 1 | 2009 | 23 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2016 | 847 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2010 | 398 | 0.020 |
Why?
|
| Serine | 1 | 2010 | 394 | 0.020 |
Why?
|
| Diphosphonates | 1 | 2011 | 264 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1206 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 602 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2002 | 2256 | 0.020 |
Why?
|
| ABO Blood-Group System | 1 | 2009 | 125 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 1146 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 2199 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 1445 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2010 | 207 | 0.020 |
Why?
|
| Receptor, ErbB-3 | 1 | 2009 | 126 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2009 | 99 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 2452 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2009 | 397 | 0.020 |
Why?
|
| Growth Inhibitors | 1 | 2008 | 164 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2007 | 66 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 1581 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 541 | 0.020 |
Why?
|
| Chromatin | 1 | 2013 | 1044 | 0.020 |
Why?
|
| Decision Trees | 1 | 2007 | 181 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2010 | 1360 | 0.020 |
Why?
|
| Metformin | 1 | 2011 | 394 | 0.020 |
Why?
|
| Genome, Human | 1 | 2015 | 1886 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 1099 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 751 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 3621 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2012 | 1279 | 0.020 |
Why?
|
| Self Report | 1 | 2010 | 792 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 1019 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2010 | 914 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2006 | 179 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 696 | 0.020 |
Why?
|
| Adenoviruses, Human | 1 | 2006 | 191 | 0.020 |
Why?
|
| Receptors, CCR7 | 1 | 2005 | 38 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2005 | 50 | 0.020 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2005 | 58 | 0.020 |
Why?
|
| Piperidines | 1 | 2011 | 1087 | 0.020 |
Why?
|
| Immunotherapy | 1 | 1999 | 3547 | 0.020 |
Why?
|
| Methods | 1 | 1984 | 223 | 0.020 |
Why?
|
| Laminin | 1 | 2005 | 212 | 0.020 |
Why?
|
| Castration | 1 | 1984 | 122 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2005 | 159 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1984 | 480 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2009 | 681 | 0.020 |
Why?
|
| Vomiting | 1 | 2006 | 361 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2005 | 259 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2005 | 279 | 0.010 |
Why?
|
| Transgenes | 1 | 2006 | 577 | 0.010 |
Why?
|
| Nipples | 1 | 2005 | 124 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2008 | 669 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 2005 | 343 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 2 | 1 | 2003 | 5 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2003 | 9 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 7262 | 0.010 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2003 | 44 | 0.010 |
Why?
|
| Microtubules | 1 | 2005 | 330 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2005 | 591 | 0.010 |
Why?
|
| Sulindac | 1 | 2003 | 55 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 3449 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 840 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 635 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 1018 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2012 | 5740 | 0.010 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2003 | 112 | 0.010 |
Why?
|
| Blood | 1 | 2004 | 172 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 939 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 533 | 0.010 |
Why?
|
| Cathepsin D | 1 | 2002 | 33 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 1504 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2008 | 876 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2004 | 475 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2004 | 267 | 0.010 |
Why?
|
| Hysterectomy | 1 | 2006 | 653 | 0.010 |
Why?
|
| Collagen | 1 | 2005 | 729 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2005 | 503 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2005 | 723 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 7404 | 0.010 |
Why?
|
| Neutropenia | 1 | 2006 | 1001 | 0.010 |
Why?
|
| Prodrugs | 1 | 2003 | 226 | 0.010 |
Why?
|
| Growth Substances | 1 | 2002 | 328 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 944 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 531 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2004 | 486 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1416 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1984 | 1556 | 0.010 |
Why?
|
| Liposomes | 1 | 2003 | 709 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 484 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2006 | 1859 | 0.010 |
Why?
|
| Ovary | 1 | 1984 | 699 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 1437 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 2459 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 3610 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2004 | 1054 | 0.010 |
Why?
|
| Remission Induction | 1 | 2005 | 3653 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1590 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 1065 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2000 | 480 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2005 | 2572 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 894 | 0.010 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2000 | 140 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2003 | 1350 | 0.010 |
Why?
|
| Inflammation | 1 | 2006 | 2531 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2002 | 3073 | 0.010 |
Why?
|
| Rats | 1 | 1984 | 6595 | 0.010 |
Why?
|
| Pain | 1 | 2004 | 1698 | 0.010 |
Why?
|
| Skin | 1 | 1999 | 1281 | 0.010 |
Why?
|
| Child | 1 | 2010 | 30545 | 0.000 |
Why?
|
| Graft vs Host Disease | 1 | 1999 | 2809 | 0.000 |
Why?
|